Models
SHREE GANESH REMEDIES LTDSGRLPharmaceuticals & Biotechnology
₹159per share · Base Model Note
Revenue growth, the horizon and scenarios are yours to change. Every other input is part of the Trader plan; saving, sharing a saved link and the live-formula workbook are part of the Institutional plan.
Scenario
Value per share, your model₹159implied FY26 P/E 11.5× · EV/EBITDA 6.3×
Against CMP ₹705.00−77.4%close of 8 Oct 2026
Growth the CMP implies—%no growth rate between −20% and 45% a year brings the value to the CMP on your other inputs
Value after FY3176%share of enterprise value in the terminal
This figure is the arithmetic of your inputs and nothing else. MarketPing publishes no fair value, target or rating; the model is yours.
Where the methods land · ₹ per share · the dashed line is the CMP
DCF, rate ±1 · growth ±1your model across the sensitivity grid
₹121₹237
52-week rangetraded range, a fact not a value
₹477₹750
From enterprise to equity · ₹ crore
| PV of FY27–FY31 free cash flow | 54 |
| PV of terminal value | 168 |
| Enterprise value | 222 |
| less net debt | (17) |
| less non-controlling interest | 0 |
| add non-operating investments | 0 |
| Equity value | 205 |
| ÷ 1.28 crore shares | ₹159 |
76% of the value sits after FY31. Usual when return on capital sits near the cost of capital; the 5 explicit years carry little of it.
Free cash flow, filed and modelled · ₹ '000 crore
Filed, cash from operations − capexModelled free cash flow to firm
Sensitivity · ₹ per share
Down Across| WACC ↓terminal growth → | 4.0% | 4.5% | 5.0% | 5.5% | 6.0% |
|---|---|---|---|---|---|
| 10.00% | 165 | 178 | 194 | 213 | 237 |
| 10.50% | 151 | 162 | 175 | 190 | 209 |
| 11.00% | 140 | 149 | 159 | 172 | 187 |
| 11.50% | 129 | 137 | 146 | 157 | 169 |
| 12.00% | 121 | 127 | 135 | 144 | 154 |
The outlined cell is your model. Green figures sit above the CMP of ₹705.00; n/a marks a terminal growth at or above the discount rate. Steps: WACC and terminal growth ±0.5 point, growth ±2, margin ±1.
Distribution of outcomes · 4,000 draws · growth, margin and the discount rate vary together
| 10th · 50th · 90th percentile, ₹ per share | 125 · 158 · 197 |
| Draws below the CMP | 100% |
| Rank correlation with ebitda margin | +0.80 |
| Rank correlation with discount rate | −0.55 |
| Rank correlation with revenue growth | −0.01 |
Each driver is drawn from a PERT distribution between the lowest and highest value across your scenarios (or ±50% growth, ±20% margin when there is one scenario), with the discount rate ±1.5 points. Seeded, so the same inputs give the same picture.
Projected cash flow to the firm · ₹ crore
History Forward| ₹ crore | FY20 | FY24 | FY25 | FY26 | FY27 | FY28 | FY29 | FY30 | FY31 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 64 | 126 | 109 | 109 | 110 | 110 | 111 | 111 | 112 |
| growth % | — | 96.7 | (13.7) | 0.6 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 |
| EBITDA | 13 | 42 | 39 | 35 | 35 | 35 | 35 | 36 | 36 |
| margin % | 19.6 | 33.2 | 36.1 | 32.0 | 32.0 | 32.0 | 32.0 | 32.0 | 32.0 |
| less depreciation | (2) | (6) | (10) | (10) | (11) | (11) | (11) | (11) | (11) |
| EBIT | 10 | 36 | 30 | 25 | 25 | 25 | 25 | 25 | 25 |
| less tax on EBIT | (6) | (6) | (6) | (6) | (6) | (7) | |||
| NOPAT | 18 | 18 | 18 | 18 | 18 | 19 | |||
| add depreciation | 2 | 6 | 10 | 10 | 11 | 11 | 11 | 11 | 11 |
| less capex | — | (31) | (23) | (17) | (17) | (16) | (15) | (14) | (13) |
| less working-capital build | — | (0) | (0) | (0) | (0) | (0) | |||
| Free cash flow to firm | — | (1) | 7 | — | 12 | 13 | 14 | 15 | 16 |
| Discount factor | 0.949 | 0.855 | 0.770 | 0.694 | 0.625 | ||||
| Present value | 11 | 11 | 11 | 10 | 10 |
History columns are the filed years (free cash flow there is cash from operations − capex, as filed); the base year and everything to its right come from the engine. Forward is the explicit horizon of the model itself: 3, 5 or 10 years, then flat.
The three statements, projected · ₹ crore · debt held at 31, dividends at 0% of profit
| ₹ crore | FY26 | FY27 | FY28 | FY29 | FY30 | FY31 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| EBIT | 25 | 25 | 25 | 25 | 25 | 25 |
| Interest at 10.3% on debt | (3) | (3) | (3) | (3) | (3) | |
| Profit before tax | 21 | 22 | 22 | 22 | 22 | |
| Profit after tax | 18 | 16 | 16 | 16 | 16 | 16 |
| Dividends | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance sheet, year end | ||||||
| Cash | 13 | 23 | 33 | 45 | 58 | 72 |
| Working capital | 47 | 47 | 48 | 48 | 48 | 48 |
| Net block and other assets | 147 | 153 | 158 | 163 | 166 | 168 |
| Debt | 31 | 31 | 31 | 31 | 31 | 31 |
| Equity | 163 | 179 | 195 | 211 | 227 | 243 |
| Balance check | 0 | 0 | (0) | 0 | 0 | 0 |
| Cash flow | ||||||
| From operations | 26 | 26 | 26 | 27 | 27 | |
| Investing (capex) | (17) | (16) | (15) | (14) | (13) | |
| Financing (dividends) | 0 | 0 | 0 | 0 | 0 | |
| Net change in cash | 9 | 11 | 12 | 13 | 14 | |
| Free cash flow to equity | 9 | 11 | 12 | 13 | 14 | |
Other liabilities are held at their FY26 level, so the check tests only what the model moves: cash, working capital, net block and other assets, debt and equity. A non-zero check would mean the three statements no longer tie.
Scenarios side by side · ₹ per share
| Scenario | Template | Growth | Margin | Rate | Terminal | ₹ / share | vs CMP |
|---|---|---|---|---|---|---|---|
| Base · editing | DCF | 0.5% | 32% | 11.00% | 5% | ₹159 | (77.4)% |
A scenario is a full set of inputs under a name. Keep Base as the filed history carried forward; add Bull and Bear by saving the current inputs under those names and moving the two or three assumptions you actually hold a view on. The distribution above draws each driver between the lowest and highest value across your scenarios, so three scenarios give it a real range; with one scenario it falls back to fixed bands.